Welcome to our dedicated page for Allakos SEC filings (Ticker: ALLK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allakos Inc. (ALLK) SEC filings page on Stock Titan is intended to centralize access to the company’s regulatory disclosures once they are available through the EDGAR system. Allakos is a clinical stage biotechnology company whose public communications describe a focus on antibody therapeutics targeting immunomodulatory receptors on immune effector cells involved in allergy, inflammatory and proliferative diseases.
For a company such as Allakos, annual reports on Form 10‑K and quarterly reports on Form 10‑Q, when filed, typically provide detailed information on research and development activities, clinical trial progress for candidates like AK006, restructuring actions, cash, cash equivalents and investments, and risk factors related to drug development and capital markets. Current reports on Form 8‑K, when issued, are used to disclose material events, which for Allakos have included program halts, restructuring plans, and the announcement of a definitive merger agreement under which Concentra Biosciences, LLC will acquire Allakos through a tender offer and merger, subject to stated conditions.
Although no specific filings are listed in the provided data, Stock Titan’s platform is designed to surface real-time updates from EDGAR as they are posted, and to pair them with AI-powered summaries that explain the key points in accessible language. This can help readers interpret lengthy documents such as 10‑K and 10‑Q reports, as well as any proxy statements that may discuss topics like governance, compensation frameworks, or shareholder votes related to transactions.
Users interested in Allakos’ transition through restructuring and its planned acquisition by Concentra Biosciences can use this page to monitor future SEC filings associated with the tender offer, merger closing, and any related disclosures. AI-generated overviews aim to highlight the sections most relevant to clinical development status, liquidity, and corporate changes, while still allowing direct access to the full official documents.
Schedule 13G/A filed on behalf of Beryl Capital entities and David A. Witkin reports no beneficial ownership of Allakos Inc. The filing, covering Common Stock (CUSIP 01671P100) and referencing the event date 06/30/2025, lists Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and David A. Witkin as reporting persons. Each reporting person disclaims beneficial ownership and the filing shows an aggregate amount of 0 shares (0%) for all listed filers. The document includes the issuer address, signatures dated 07/31/2025 by Andrew Nelson and David A. Witkin, a certification that the securities were acquired and held in the ordinary course of business and not to influence control, and Exhibit 99.1 (Agreement Regarding Joint Filing).
Three reporting persons filed a Schedule 13G/A for Allakos Inc. (Common Stock). The filers—Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; and David Kroin—report zero shares beneficially owned and 0.00% ownership of the class. The statement shows no sole or shared voting or dispositive power attributed to any reporting person.
The calculation of the percentage is based on the issuer's reported share count of 90,376,972 common shares outstanding. The filing includes a joint filing statement where the undersigned agree to file future amendments on behalf of each other and confirm responsibility for their respective disclosures.